loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Surufatinib

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Surufatinib

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    HUTCHMED To Present Clinical Data At ESMO And World Lung Cancer Conf
    HUTCHMED To Present Clinical Data At ESMO And World Lung Cancer Conf

    08 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/09/2942477/0/en/HUTCHMED-Highlights-Clinical-Data-to-be-Presented-at-ESMO-Congress-2024-and-the-2024-World-Conference-of-Lung-Cancer.html

    GLOBENEWSWIRE
    08 Sep 2024
    Share Share
    Hutchmed in collab with Hengrui initiate phase II/III trial of surufatinib
    Hutchmed in collab with Hengrui initiate phase II/III trial of surufatinib

    16 May 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=169178&sid=2

    PHARMABIZ
    16 May 2024
    Share Share
    HUTCHMED, Hengrui Phase 2/3 Pancreatic Cancer Trial Begins
    HUTCHMED, Hengrui Phase 2/3 Pancreatic Cancer Trial Begins

    13 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/14/2880987/0/en/HUTCHMED-Initiates-Phase-II-III-Trial-of-the-Combination-of-Surufatinib-and-Camrelizumab-for-Treatment-Na%C3%AFve-Pancreatic-Ductal-Adenocarcinoma-in-Collaboration-with-Hengrui.html

    GLOBENEWSWIRE
    13 May 2024
    Share Share
    HUTCHMED Announces Continued Inclusion of ELUNATE and SULANDA
    HUTCHMED Announces Continued Inclusion of ELUNATE and SULANDA

    12 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/13/2795215/0/en/HUTCHMED-Announces-Continued-Inclusion-of-ELUNATE-fruquintinib-and-SULANDA-surufatinib-in-the-National-Reimbursement-Drug-List-in-China-at-Current-Terms.html

    GLOBENEWSWIRE
    12 Dec 2023
    Share Share
    FDA rejects two China-developed cancer drugs
    FDA rejects two China-developed cancer drugs

    03 May 2022

    // J. Gardner BIOPHARMADIVE

    https://www.biopharmadive.com/news/fda-reject-hutchmed-junshi-china-developed-cancer-drug/623024/

    J. Gardner BIOPHARMADIVE
    03 May 2022
    Share Share
    Hutchmed announces agreement with NHSA for adding oncology drugs Elunat
    Hutchmed announces agreement with NHSA for adding oncology drugs Elunat

    06 Dec 2021

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=144446&sid=2

    PHARMABIZ
    06 Dec 2021
    Share Share